Chief Executive Officer
CurrentAt Epitopea we know that better cancer therapies are needed to transform patient responses and their lives. Epitopea is the global leader in exploiting a novel class of untapped, aberrantly expressed tumor-specific antigens (aeTSAs) or CryptigenTM TSAs that are shared across multiple patients with the same tumor type. We leverage these differentiated.